Rubius Therapeutics (RUBY) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RUBY Hot Sheet
Join SI Premium – FREE
Rubius Therapeutics (NASDAQ: RUBY) reported Q2 EPS of ($0.49), $0.04 better than the analyst estimate of ($0.53).
For earnings history and earnings-related data on Rubius Therapeutics (RUBY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oscar Health Inc. (OSCR) Tops Q3 EPS by 63c ; Offers Guidance
- Genesis Energy (GEL) Misses Q3 EPS by 8c
- Ship Finance (SFL) Tops Q3 EPS by 14c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
